ABSTRAK
INTRODUCTION
Stenting in Coronary have provided significant clinical improvement in patients undergoing percutaneous Transluminal Coronary Angioplasty (PTCA). But there kompilkasi Stent thrombosis (ST) coronary rare, but serious that can cause high morbidity and mortality (Palmerini et al 2011 , Wenaweser et al 2005 , Brener et al 2013 . The incidence of ST is increased in patients undergoing PTCA with acute coronary syndromes, patients who have diabetes mellitus, or bifurcatio stenting in patients who stopped dual anti-platelet therapy (Brener et al 2013) . Stent thrombosis associated with acute ischemia, infarction, hemodynamic instability and death (Antolin 2004) . Intraprosedural stent thrombosis (IPST) is a new thrombus formation leading to occlusion or during or shortly after stent implantation before PTCA procedure is completed (Brener et al 2013) . The following will be reported a case IPST during PTCA action.
CASE REPORT
A woman named Mrs. WSD, 44 years old, Javanese, Muslim, located in Malang, housewives, with Askes financing status, go to hospitals Dr Soetomo on January 22, 2013 at 20:00 pm with a chief complaint of chest pain left three weeks ago , Chest pain is felt like being stabbed through to the back, left arm and neck. Chest pain was advancing since two days before entering the hospital with a duration of more than 20 minutes, and intermittent. Pain is also felt when berisitirahat. Previous sufferers often complain of chest pain since one year ago perceived intermittent and disappear when taking medication ISDN. There were no nausea, vomiting, palpitations, shortness of breath, cold sweats or fainting.
Patients had a history of suffering from hypertension and dyslipidemia since three years ago but not regularly take medication. Patients treated for heart specialists in Malang and getting medicine Isosorbide dinitrate (ISDN) 3x5 mg, clopidogrel 1x75 mg, 1x40 mg Ator-vastatin night, Acetyl Salicylate Acid (ASA) 1x80 mg, lisinopril 2x2,5 1x0,5 mg Alprazolam mg and night. Denying patients suffering from diabetes mellitus, history of smoking. A family history of patients who suffer heart as well not exist.
On physical examination found the general condition is weak with blood pressure 125/85 mm Hg, pulse 71 beats/min regular, respiratory rate 21 breaths/min, axillary temperature of 37 0 C. At the head of the inspection found no abnormality. On examination of the heart obtained iktus apex in V intercostal space mid clavicular line parallel to the left, with the sound of S1-S2 single, regular, no sound is obtained extrasystoles, gallop, or murmur. On examination discovered pulmonary crackles, wheezing or other abnormalities. On abdominal examination found no abnormality, normal bowel sounds. On examination of the lower extremity leg edema was not found with legs felt warm and dry.
On examination of the sinus rhythm ECG obtained 85 times/minute, normal axis (normal ECG). While in the chest X-ray examination found the heart and lungs within normal limits. In laboratory tests dated January 22, 2013 obtained hemoglobin 12.5 g/dL, 9.1 leukocytes/uL, platelets 294,000/uL, hematocrit 37.5%, GDA 81 mg/dL, BUN 7.7 mg/dL, serum creatinine 0.61 mg/dL, AST 18 U/I, ALT 13 U/I, Sodium 141 mmol/L, potassium 4.1 mmol/L, Chloride 109 mmol/L, LDH 312, 19.4 CKMB repeated 6 hours later to 12.5. Troponin negative repeated 6 hours later remains negative. BGA: PH 7.47 27 pCO2, pO2 107 HCO3 19.7, -4.0 BE SO2 98%.
Patients diagnosed as unstable angina with 2 TIMI Risk Score and controlled hypertension. Patients receive infusion therapy NaCl 0.9% to 500 cc/24 hours, ISDN 3x5 mg, clopidogrel 1x75 mg, 1x40 mg Atorvastatin night, Acetyl Salicylate Acid (ASA) 1x80 mg, lisinopril 2.5 mg-0 to 2.5 mg, 1x0,5 mg alprazolam night. Because they felt chest pain, Isosorbide dinitrate (ISDN) ISDN pump replaced with a tablet of 0.5 mg/hr.
On the second day of treatment (January 23, 2013) has been reduced complaints of chest pain, blood pressure 139/77 mm Hg, pulse 76 beats/minute, respiratory rate 18 breaths/min. Therapy followed by addition lactulosa 3x1 tablespoons syrup. Treatment third day (January 24, 2013) Of coronary angiography are found appears the intracoronary thrombus on the stent in the distal LMCAproximal LAD and mid LAD. Diagnosed as acute stent thrombosis. Thrombus aspiration is done with Thrombuster II 7F and earned a red thrombus is then given 12 cc intracoronary eptifibatide. Suddenly the blood pressure back down TD 82/63 mmHg. Norephinephrin raised to 300 NCG/KgBW/min and dopamine given 10 mcg/kg/min. O2 saturation fell to 90% with inadequate breathing. Then intubate Peer anesthesia with midazolam premedication. Back thrombus aspiration using thrombuster II 7F and earned a red thrombus. Blood pressure rose to 150/88 mmHg. Norephinephrin dose was lowered to 100 NCG/KgBW /min and maintained. Improved blood pressure 117/60 mmHg, Heart rate 103 beats/min with TPM gives a chance 90 times/min sensitivity of 5 mV and output 5, RR 15 breaths/min with O2 saturation of 95%. Good results, TIMI flow 3, there is a residual stenosis <50%.
Eptifibatide continued maintenance 8 cc/hour for 12 hours, then continued enoxapharin 2x0.6 cc subcutaneous and clopidogrel given 1x75 mg po, Amiodarone 600 mg iv pump for 18 hours. Furthermore, the patients treated in the Intensive Care Unit (ICU Based on the time of occurrence of stent thrombosis can be grouped into four acute stent thrombosis (0-24 hours after stent implantation), subacute stent thrombosis (24 hours -30 days after stent implantation), late stent thrombosis (30 days -1 year post implantation of the stent) and very late stent thrombosis (> 1 year) (Bhatt & Hauser 2008 , Mitchell et al 2008 . Acute Stent Thrombosis is an event typical chest pain that occurs suddenly with a change in the form of acute ischemic ECG picture in accordance with the distribution of the affected blood vessel arising <24 hours after the act of stenting in coronary interventions. In angiography, stent thrombosis is a complete or partial occlusion of the blood vessel segments mounted stent, with evidence of thrombus (Wenaweser et al 2005) . According Brener et al (2013) , issued by the ST category based on only ARC stent thrombosis events that arise after the patient out of the cardiac catheterization laboratory, not at the time of intra-procedural. Then Brener et al define intraprocedural stent thrombosis (IPST) as the formation of a new thrombus or increased thrombus compared to baseline its cause occlusion or during or shortly after stent implantation before PTCA procedure is completed. Intra-procedural stent thrombosis (IPST) also occurs when a thrombus baseline diminished or disappeared after the action looked balloon angioplasty or thrombus aspiration of thrombus but then increased anytime after stent implantation (including post stent dilation) (Brener et al 2013) . In people, as soon as the action predilatasi with balloon and stent in the LAD DES-LMCA, there was an intracoronary thrombus at the distal LMCA with a duration of less than 24 hours. This corresponds to a diagnosis of intra-procedural stent thrombosis. And by less than 24 hours including acut definitive stent thrombosis.
The risk factors have been identified which could increase the occurrence of stent thrombosis can be divided into: derived from the characteristics of the patient, lesion characteristics and procedural factors/ properties of the stent. Patient characteristics include: gene polymorphism, the use of anti-platelet inadequate, resistance antiplatelet effect of Acetyl Salysilat Acid (ASA) and a thienopyridine class (Wenaweser et Factors procedural include stent expansion incomplete, malposition stent, a stent is placed in the target small blood vessels or use the diameter stent is a small, placement of multiple stents (especially the implantation of a stent in bifurcation and overlapping stents), stent placed over thrombus existing or stent placed over the stent contained residual dissection or thrombus before What type of stent? At the beginning of the era of BMS, as many as 20% of patients had ST which mostly arise within 2 days after PTCA. Then after DAPT usage and high pressure post-dilatation, the incidence of ST within 30 days of the BMS is very small due to have undergone a complete endotelialisasi. In the era of DES, lift ST events occurred more frequently in less than 30 days due to the slow endotelialisasi result of drug contained within the stent. A meta-analysis with 9471 patients from 22 randomized studies found that there was no difference between BMS and DES in terms of overall mortality (hazard ratio (HR) 0.97; 95% Confidence Interval (CI) 0.81-1.15; P = 0.72) or myocardial infarction (HR 0.95; 95% CI 0.79-1.13; P = 0.54) between the use of DES with BMS (Buchanan et al 2012) . Similarly, the results of Acuity study, there was no significant difference between the incidence of ST BMS and DES (1.4% versus 1.4%; P = 1.00) (Aoki et al 2009) . Although there are studies on animals that get first-generation DES mainly Rapamycin is thrombogenic (Camici et al 2010) . Of the type DES itself turns out there are differences in the incidence of ST. The following table study on a second-generation DES and the incidence of ST (Buchanan et al 2012) . Biolimus is the latest generation DES a biodegradable polylactide polymer that is metabolized filled within 6-9 months. From the study randomization "Limus eluted from A Durable versus ERodable Stent coating" (LEADERS) as many as 1,707 patients who received sirolimus (SES) or biolimus A9 (BES) were followed for 3 years showed definite ST 2.2% for BES and 2.9% for SES ( HR 0.78; 95% CI 0:43 to 1:43; P = 0.43) (Buchanan et al 2012) .
The risk factors that occur include patients with acute coronary syndromes (unstabil Angina) and the presence of lesions in the bifurcation of the LAD as high as Diagonal 1. Then multiple stent mounted around bifurcation lesions such as Rapamycin DES stenting 2.5x33 mm in mid LAD and stent DES Biolimus 3 , 5x18 mm proximal to the mid LAD-overlapping with the stent in mid LAD and complicating coronary dissection at the distal LM. This is in accordance with risk factors for patient characteristics, lesion characteristics and procedural form of Unstable Angina with multiple stenting, overlap mainly in bifurcation stent placement and coronary dissection.
Pathogenesis of stent thrombosis
The pathogenesis of ST has not been known. Many factors are involved including procedural factors/stent, patient factors and lesion characteristics. Patients with acute coronary syndrome, inflammation and tissue necrosis were exposed to the circulation so as to strengthen the activity of platelets and easily formed thrombus (Lüscher et al 2007) . A stent is a foreign object inside the walls of blood vessels. The material in the form of a polymer stent Cypher (sirolimus) and Taxus (paclitaxel) DES can cause infiltration of eosinophils suspected hypersensitivity reaction can trigger platelet adhesion and activation cascade coagulant.
The presence of vascular injury when stenting complications such as coronary dissection can lead to exposure of thrombogenic molecules of subintima and media (including plaque material) into the bloodstream (Lüscher et al 2007) . This evidenced the fragments of atherosclerotic plaque as foam macrophages, cholesterol crystals and a thin fibrous cap of thrombus aspiration results in ST (Steg et al 2012) . Also found in the platelet cells, inflammatory cells such as neutrophils, macrophages and eosinophils as well as red blood cells trapped (Braunersreuther et al 2012) . Exposure of subendothelial matrix circulation to cause activation of platelets to aggregate, causing thrombus (Yamaji et al 2012 , Kumar & Cannon 2009 ) if anti platelets respond. Table 3 . Study of Second Generation DES and the incidence of stent thrombosis (Buchanan et al 2012)
The content of the drugs currently on the DES can be protrombogenik. Rapamycin and Paclitaxel works by blocking the migration and proliferation of smooth muscle cells that plays a role in neointimal formation and restenosis. However, both drugs induce endothelial expression of tissue factor that will bind to the clotting factor so that the formation of fibrin (Lüscher et al 2007) .
There are two kinds of white thrombus thrombus namely: a platelet-rich thrombus, usually only lead to partial occlusion and red thrombus: a rich thrombus fibrin and erythrocytes (Kumar & Cannon 2009 ). The red thrombus is superimposed with white thrombus which aggregate to rupture/erosion plaque that will increase the formation of fibrin. Fibrin is formed to trap red cells and inflammatory cells such as cells myeloperoxidase, a strong pro-oxidants. Myeloperoxidase cell will attract and activate neutrophils which will induce erythrocytes hyperagrebility (Brener et al 2013) .
Stent thrombosis management

Preventing stent thrombosis
Handling of stent thrombosis most important thing is to take reasonable precautions to reduce the risk factors and procedural optimization. Dual anti-platelet (DAPT) should be given as early as possible, especially in all patients with acute coronary syndrome patients that screening adherence to DAPT use, the risk of bleeding and the operation plan within 12 months after PTCA is important (Buchanan et al 2012 , Hamm et al 2011 . Acetylsalicylic acid (ASA) and the P2Y12 receptor antagonists such as clopidogrel, prasugrel and ticagrelor served to increase the effectiveness of treatment and prevention of thrombosis (Hamm et al 2011) . The use of dual anti-platelet therapy (ASA and clopidogrel) reduces the incidence of thrombosis but increase bleeding complications. The incidence of stent thrombo-sis could still occur at 0.5-2% in the case of elective PCI and more than 6% in the case of PCI with acute coronary syndromes despite using dual antiplatelet (Wenaweser et al 2005) . In the CURRENT OASIS study comparing the use of clopidogrel dose of 150 mg/day for one week compared to the standard dose of 75 mg/day obtained a significant reduction definite or probable stent thrombosis (HR 0.69; 95% CI -0.87 0:56; P = 0.001) (Hamm et al 2011) . Patients in this study had a routine therapy 1x100 mg ASA and clopidogrel 1x75 mg. And after PTCA get Clopidogrel 2 x 75 mg for one week followed Clopidogrel 1 x 75 mg.
Selection of anticoagulation during PCI procedures is also important. Unfractionated heparin (UFH) is the main option while undergoing PCI. Combination with glycoptrotein IIa/IIIb inhibitors especially Abciximab (research Cadillac) indicates there are no predictors ST. From the research HORIZON-AMI, comparing UFHGlycoprotein IIa/IIIb with direct thrombin inhibitors bivalirubin as monotherapy, showed a 0.3 vs 1.4%, P <0.001 in the incidence of Acute ST (Buchanan et al 2012 , Dangas et al 2011 . Receptor GP IIb/IIIa receptor on the platelet surface there are many. When platelet activation occurs, these receptors undergo structural changes that will increase its affinity for binding with fibrinogen and other ligands. The workings of GP IIb/IIIa inhibitors is binds to this receptor, thereby preventing the binding of fibrinogen and ultimately inhibit platelet aggregation (Harrington et al 2008) . Three classes of GP IIb/IIIa inhibitor approved clinical use, namely abciximab, eptifibatide and tirofiban (Wright et al 2011) . In this study, when the initial act of PCI, patients receiving heparin therapy Ui 7500 iv bolus.
Implatasi for stent procedures, as much as possible to eliminate the space between the frame stent with the vessel wall. Their stent malposition will facilitate the formation of thrombus. Penetration order stent on the underlying layer of necrosis will trigger inflammation and fibrin deposits and inhibit the growth of neo-intima causing the stent framework is not covered. Likewise decrease epikardial flow, vasoconstriction, thrombus and plaque terembolisasi aterom fragile and underexpansion will lead undersizing of the stent during the procedure ( To further optimize the prevention ST, lesions calsified, can be handled with the use of rotational atherectomy so that expansion and better positioning stent. The use of intracoronary imaging modalities such as Intra Vascular Ultra Sound (IVUS) and Optical Coherence Tomography (OCT) is very helpful as guiding the expansion and apposition of the stent to be more adequate (Buchanan et al 2012) . Also look for mechanical predisposing factors underlying ST (Yunoki et al 2012) .
Overcoming stent thrombosis If ST is the case then action targets PTCA for revascularization of blood vessels should be done immediately. Guidewire selected must be soft and floppy to ensure free through the lumen of the stent and not crossing through the strut stent (Antolin 2004) . The presence of intracoronary thrombus in addition to causing occlusion may also increase the risk of distal embolization. Aspiration trombektomi intra coronary thrombus or effective for the treatment of ST especially on stents with a diameter of more than 2.5 mm, large blood vessels and large thrombus (Kleinschmidt 2006) . Intracoronary thrombus aspiration can prevent distal embolization. This procedure is performed several times until angiographically visible thrombus no longer (Alfonso et al 2004) . The existence of intra coronary thrombus is also an indication of the provision of Glycoprotein IIb-IIIa inhibitors (class IIa LOE B) (Wright et al 2011 , Sousa & Mattos 2007 . Bivalurubin also be an option. If found the phenomenon of slow flow or no flow, intracoronary adenosine and epinephrine can be given (Alfonso et al 2004) . The success of overcoming the acute thrombosis, characterized by normal blood flow (TIMI 3 flow) with stenosis <50% (Wenaweser et al 2005) .
For guiding wire used in these patients is Asahi Rinato that is floppy. When found the thrombus intracoronary at the distal LM and mid LAD, given eptifibatide at a dose of 12 cc bolus and continued maintenance doses of 8 cc/hour for 12 hours and aspiration of thrombus with Thrombuster II 7F twice to angiographically not look and found a thrombus red. The final result obtained TIMI 3 flow and no angiographically visible thrombus Patients had suffered a coronary artery dissection, symptomatic bradycardia, second-degree AV block type 2 and cardiac arrest. Coronary dissection is one of the complications of PTCA. 0.03% of the number of events throughout the action PTCA. The presence of coronary dissection, requiring additional stents to overcome (Wenaweser et al 2005) . Bradycardia is one of the complications that arise from the action PTCA. Bradycardia may arise from the use of hyperosmolar contrast, blockage especially distal coronary arteries or the reaction of vasovagal reflex due to puncture, high emotional state, dehydration and pain (Antolin in 2004 , Mitchell et al 2008 . Severe bradycardia can induce hypotension, change in mental status, symptoms of shock, ischemic chest pain or acute heart failure (Hazinski et al 2010a) .
Therapy Cardiac arrest during PTCA action together with standard therapy. There are no randomized controlled studies that evaluate alternative treatment strategies compared to the standard treatment for cardiac arrest when PTCA (Hazinski et al 2010b) . Installation of endo tracheal tube (ETT) is considered the optimal method to keep the airway during cardiac arrest with a target oxygen saturation> 95% and prevent hyperventilation, which can decrease cardiac output. Ventilator starts with breathing 10-12 breaths/min and titrated to achieve PETCO2 Pa CO2 of 35-40 mmHg or 45-45 mmHg (Peberdy et al 2010) .
CONCLUSION
It has been reported the case of a female patient, aged 44 years, came to the emergency room complaining of chest pain specifically, a risk factor for hypertension and dyslipidemia with ECG and cardiac markers within normal limits. Unstable angina patients diagnosed as a result of coronary angiography with double vessel disease and left main disease. Do PTCA with stents and coronary dissection obtained complications, symptomatic bradycardia, and cardiac arrest IPST. Do granting Glycoprotein IIIa/IIb eptifibatide, resuscitation, installation of temporary pacemaker and thrombus aspiration and successfully mitigate IPST and cardiac arrest.
